[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Zhengguo Chen\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":40},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":4},"100579652","phase-1-study-on-the-safety-tolerability-and-preliminary-efficacy-of-161tb-nym032-in-patients-with-metastatic-castration-resistant-prostate-cancer-100579652",false,"NCT06827080","Study on the Safety, Tolerability, and Preliminary Efficacy of 161Tb-NYM032 in Patients with Metastatic Castration-Resistant Prostate Cancer","\\*\\*1. Inclusion Criteria\\*\\*\n\n1. The participant voluntarily signs the informed consent form and is able to complete the trial according to the protocol requirements.\n2. Male, aged 18 years or older.\n3. Diagnosed with metastatic castration-resistant prostate cancer (mCRPC) as per PCWG3 criteria.\n4. Positive results on 68Ga-NYM032 positron emission tomography (PET)\u002Fcomputed tomography (CT) scan.\n5. Must have received at least one NAAD treatment (e.g., enzalutamide and\u002For abiraterone) or at least one taxane-based treatment regimen, or be intolerant to or refuse taxane therapy for metastatic castration-resistant prostate cancer.\n6. ECOG performance status of 0-2.\n7. Expected survival of ≥6 months.\n8. Laboratory parameters must meet the following:\n\n   1. ALT and AST must not exceed 3 times the upper limit of normal (ULN); BUN and Cr must not exceed 1.5 times the ULN.\n   2. Blood counts: WBC ≥3.5×10\\^9\u002FL, PLT ≥100×10\\^9\u002FL, Hb ≥90 g\u002FL.","MALE","18 Years",{"count":18,"type":19},15,"ESTIMATED","INTERVENTIONAL",[22,23],"PHASE1","PHASE2","161Tb-NYM032 is a radiopharmaceutical labeled with a PSMA ligand, used for the treatment of metastatic castration-resistant prostate cancer, which is needed for clinical trial to be conducted.",[26,27],"Metastatic Castration-resistant Prostate Cancer, MCRPC","Cancer","NOT_YET_RECRUITING","2025-02-10",{"date":31,"type":32},"2025-02-14","ACTUAL",{"date":34,"type":19},"2025-02-11",{"date":36,"type":19},"2026-12-01",{"name":38,"class":39},"Zhengguo Chen","OTHER",""]